vs

Side-by-side financial comparison of AbCellera Biologics Inc. (ABCL) and Bridgewater Bancshares Inc (BWB). Click either name above to swap in a different company.

Bridgewater Bancshares Inc is the larger business by last-quarter revenue ($46.2M vs $44.9M, roughly 1.0× AbCellera Biologics Inc.). Bridgewater Bancshares Inc runs the higher net margin — 37.7% vs -19.9%, a 57.6% gap on every dollar of revenue. Over the past eight quarters, AbCellera Biologics Inc.'s revenue compounded faster (112.3% CAGR vs 31.4%).

AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.

Bridgewater Bancshares Inc. is a regional bank holding company headquartered in Minnesota, U.S. It offers a full suite of commercial and retail banking services including business loans, deposit products, residential mortgages, and personal banking solutions, primarily serving SMEs, individual consumers and local commercial clients in its operating areas.

ABCL vs BWB — Head-to-Head

Bigger by revenue
BWB
BWB
1.0× larger
BWB
$46.2M
$44.9M
ABCL
Higher net margin
BWB
BWB
57.6% more per $
BWB
37.7%
-19.9%
ABCL
Faster 2-yr revenue CAGR
ABCL
ABCL
Annualised
ABCL
112.3%
31.4%
BWB

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ABCL
ABCL
BWB
BWB
Revenue
$44.9M
$46.2M
Net Profit
$-8.9M
$17.4M
Gross Margin
Operating Margin
-63.7%
Net Margin
-19.9%
37.7%
Revenue YoY
788.4%
Net Profit YoY
73.9%
80.7%
EPS (diluted)
$-0.03
$0.58

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ABCL
ABCL
BWB
BWB
Q1 26
$46.2M
Q4 25
$44.9M
$38.8M
Q3 25
$9.0M
$36.2M
Q2 25
$17.1M
$36.1M
Q1 25
$4.2M
$32.3M
Q4 24
$5.0M
$29.5M
Q3 24
$6.5M
$27.1M
Q2 24
$7.3M
$26.8M
Net Profit
ABCL
ABCL
BWB
BWB
Q1 26
$17.4M
Q4 25
$-8.9M
$13.3M
Q3 25
$-57.1M
$11.6M
Q2 25
$-34.7M
$11.5M
Q1 25
$-45.6M
$9.6M
Q4 24
$8.2M
Q3 24
$-51.1M
$8.7M
Q2 24
$-36.9M
$8.1M
Operating Margin
ABCL
ABCL
BWB
BWB
Q1 26
Q4 25
-63.7%
44.2%
Q3 25
-851.8%
41.8%
Q2 25
-290.2%
42.0%
Q1 25
-1479.6%
39.2%
Q4 24
35.6%
Q3 24
-1439.4%
41.9%
Q2 24
-1276.2%
39.7%
Net Margin
ABCL
ABCL
BWB
BWB
Q1 26
37.7%
Q4 25
-19.9%
34.3%
Q3 25
-637.8%
32.1%
Q2 25
-203.3%
31.9%
Q1 25
-1077.2%
29.8%
Q4 24
27.8%
Q3 24
-785.4%
32.0%
Q2 24
-504.3%
30.3%
EPS (diluted)
ABCL
ABCL
BWB
BWB
Q1 26
$0.58
Q4 25
$-0.03
$0.42
Q3 25
$-0.19
$0.38
Q2 25
$-0.12
$0.38
Q1 25
$-0.15
$0.31
Q4 24
$0.26
Q3 24
$-0.17
$0.27
Q2 24
$-0.13
$0.26

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ABCL
ABCL
BWB
BWB
Cash + ST InvestmentsLiquidity on hand
$128.5M
$222.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$966.9M
$528.4M
Total Assets
$1.4B
$5.3B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ABCL
ABCL
BWB
BWB
Q1 26
$222.2M
Q4 25
$128.5M
$123.5M
Q3 25
$83.2M
$131.8M
Q2 25
$92.4M
$217.5M
Q1 25
$159.3M
$166.2M
Q4 24
$156.3M
$229.8M
Q3 24
$126.6M
$191.9M
Q2 24
$148.3M
$134.1M
Stockholders' Equity
ABCL
ABCL
BWB
BWB
Q1 26
$528.4M
Q4 25
$966.9M
$517.1M
Q3 25
$964.0M
$497.5M
Q2 25
$1.0B
$476.3M
Q1 25
$1.0B
$469.0M
Q4 24
$1.1B
$457.9M
Q3 24
$1.1B
$452.2M
Q2 24
$1.1B
$439.2M
Total Assets
ABCL
ABCL
BWB
BWB
Q1 26
$5.3B
Q4 25
$1.4B
$5.4B
Q3 25
$1.4B
$5.4B
Q2 25
$1.4B
$5.3B
Q1 25
$1.3B
$5.1B
Q4 24
$1.4B
$5.1B
Q3 24
$1.4B
$4.7B
Q2 24
$1.4B
$4.7B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ABCL
ABCL
BWB
BWB
Operating Cash FlowLast quarter
$-34.7M
Free Cash FlowOCF − Capex
$-44.6M
FCF MarginFCF / Revenue
-99.4%
Capex IntensityCapex / Revenue
21.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-174.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ABCL
ABCL
BWB
BWB
Q1 26
Q4 25
$-34.7M
$27.8M
Q3 25
$-52.6M
$9.4M
Q2 25
$-32.4M
$4.0M
Q1 25
$-11.6M
$7.5M
Q4 24
$-108.6M
$46.4M
Q3 24
$-28.9M
$-6.0M
Q2 24
$-30.0M
$10.6M
Free Cash Flow
ABCL
ABCL
BWB
BWB
Q1 26
Q4 25
$-44.6M
$22.0M
Q3 25
$-61.5M
$7.8M
Q2 25
$-45.8M
$2.8M
Q1 25
$-22.2M
$6.9M
Q4 24
$-187.0M
$42.3M
Q3 24
$-47.4M
$-6.5M
Q2 24
$-50.1M
$10.4M
FCF Margin
ABCL
ABCL
BWB
BWB
Q1 26
Q4 25
-99.4%
56.6%
Q3 25
-687.0%
21.5%
Q2 25
-267.9%
7.8%
Q1 25
-524.0%
21.5%
Q4 24
-3702.8%
143.4%
Q3 24
-728.4%
-23.8%
Q2 24
-683.8%
38.9%
Capex Intensity
ABCL
ABCL
BWB
BWB
Q1 26
Q4 25
21.9%
15.1%
Q3 25
99.7%
4.4%
Q2 25
78.2%
3.2%
Q1 25
251.1%
1.7%
Q4 24
1552.7%
13.8%
Q3 24
284.6%
1.7%
Q2 24
274.6%
0.7%
Cash Conversion
ABCL
ABCL
BWB
BWB
Q1 26
Q4 25
2.09×
Q3 25
0.81×
Q2 25
0.35×
Q1 25
0.77×
Q4 24
5.65×
Q3 24
-0.69×
Q2 24
1.31×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ABCL
ABCL

Segment breakdown not available.

BWB
BWB

Net Interest Income$36.6M79%
Noninterest Income$9.6M21%

Related Comparisons